Heart failure drug delivery tested in healthy volunteers
NCT ID NCT07656454
First seen Jun 20, 2026 · Last updated Jun 22, 2026 · Updated 1 time
Summary
This early-stage study tests a new drug called CDR132L in 32 healthy adults. Researchers want to see how much of the drug gets into the blood when given as a shot under the skin compared to an IV drip. The goal is to find the best way to give this medicine to people with heart failure in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Parexel International GmbH
Berlin, 14050, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CDR132L
What this could lead to
If successful, this study could help determine the best way to give CDR132L to people with heart failure, potentially improving treatment convenience and effectiveness.
What could go wrong
This is a very early Phase 1 study in only 32 healthy people, so results may not predict how the drug works in heart failure patients. The drug may also have unknown side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.